USA flag logo/image

An Official Website of the United States Government

Brachytherapy Delivery System for Treatment of Lung Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85412
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA125999
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Brachytherapy Delivery System for Treatment of Lung Cancer
Agency: HHS
Contract: 2R44CA125999-02
Award Amount: $750,394.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase II program intends to continue to develop an improved brachytherapy delivery system for treatment of lung cancer by incorporating radioactive 169Ytterbium sources into surgical staples used in lung resect ion. For patients with compromised cardiopulmonary status, the inclusion of brachytherapy with sublobular resection has shown a significant improvement in therapeutic outcome over sublobular resection alone. Brachytherapy has the obvious advantage of maxim ally irradiating the tumor bed while sparing surrounding normal tissue from the field of radiation. This approach has been especially useful when the required radiation dose exceeds the tolerance dose of the surrounding normal tissues. However, logistic is sues have limited the application of brachytherapy in these lung cancer applications. This development will facilitate and dosimetrically improve the delivery of this therapy. The incorporation of 169Ytterbium sources into the surgical staples normally use d during the lung resection procedure will permit the application of lung brachytherapy at the same time as the surgery is being performed. The problem facing the current technique is in the ability to precisely deliver the brachytherapy sources intraopera tively to achieve the proper dose distribution and minimize the radiation dose to the clinicians performing the procedure. Our development would facilitate the precise placement of 169Ytterbium sources relative to the surgical margin, assure the sources re main fixed in their precise position for the duration of the treatment, overcome the technical difficulties of manipulating the sources through the narrow surgical incision, and reduce the radiation dose to the clinicians. We anticipate that this developme nt will extend the use of brachytherapy to a much larger number of compromised lung cancer patients for whom more traditional surgical procedures, such as lobectomy, are not an option. PUBLIC HEALTH RELEVANCE: This development will afford the ad ditional clinical benefit of brachytherapy to patients with compromised cardiopulmonary status, thereby improving their outcomes. The improved dose distribution resulting from more precise source positioning and fixation is expected to improve the currentl y identified clinical benefit of brachytherapy due to the limitations of the current technique. Because lung cancer is the leading cause of cancer deaths in the United States, any improvement in clinical outcome resulting from this program will translate i nto significant societal benefit.

Principal Investigator:

John J. Munro
9783400156
JOHNM@SPEC150.COM

Business Contact:


johnm@spec150.com
Small Business Information at Submission:

SOURCE PRODUCTION AND EQUIPMENT COMPANY
113 TEAL ST ST. ROSE, LA 70087

EIN/Tax ID: 172074929
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No